NCT02796781

Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Shanghai East Hospital · Academic / Other
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Interstitial lung diseases (ILD) are a group of diseases affecting the lung interstitium. The lung scarring that occurs in ILD is often irreversible with only mitigating therapy available so far. This study intends to carry out an open, single-armed, phase I/II clinical trial to investigate whether lung stem cells can regenerate damaged lung tissue. During the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in vitro. After careful characterization, cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy. The safety and efficacy of the treatment will be monitored by measuring the key clinical indicators.

Conditions

• Interstitial Lung Diseases

Interventions

Type	Name	Description
BIOLOGICAL	Lung stem cells	Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.

Timeline

• Start date: 2016-10-12
• Primary completion: 2020-08-31
• Completion: 2020-08-31
• First posted: 2016-06-13
• Last updated: 2023-10-17

Locations

1 site across 1 country: China